FL-SUN-NUCLEAR
29.4.2024 22:31:33 CEST | Business Wire | Press release
Sun Nuclear, a Mirion Medical company, today announced the upcoming version 5.0 release of its SunCHECK® software for comprehensive Quality Management in radiation therapy. The SunCHECK software is used globally by radiation therapy departments to manage delivery system oversight and patient-specific treatment quality --- all in one platform. SunCHECK Version 5.0 introduces a broad range of features and user-driven enhancements that optimize workflows and prioritize patient safety.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240429991805/en/
Sun Nuclear, a Mirion Medical company, announced the upcoming version 5.0 release of its SunCHECK® software for comprehensive Quality Management in radiation therapy. SunCHECK v5.0 addresses clinical workflow challenges with new treatment plan assessment capabilities, enhanced TPS/OIS integration, expanded QA device control, and worklist-based UI. (Graphic: Business Wire)
The Connected Workspace for Higher Quality
Toward a vision of a truly connected ecosystem for quality assurance in radiation therapy, key enhancements in SunCHECK v5.0 include:
- Better, earlier understanding of treatment plan quality and departmental standards from new plan feasibility evaluation and plan complexity metric features
- Stronger continuity of clinical goals and data management when moving from linac treatment planning system (TPS)/oncology information system (OIS) into the SunCHECK software
- Automation of time-intensive machine quality measurements with expanded device integration with the PC Electrometer™ device and 1D SCANNER™ water tank
- At-a-glance worklists and intuitive patient and machine workflows reflected in the refreshed user interface
“In each new release of SunCHECK, we are connecting and accelerating clinical workflows, while expanding compatibility so clinicians can work effectively — regardless of their department structure or equipment. By delivering efficiency gains and easing access to critical insights on treatment quality, we can help clinicians better focus on advancing care,” said Luis Rivera, Sun Nuclear Radiation Therapy President.
Demonstrations of the latest software will be available in the Sun Nuclear booth (#930) at the ESTRO Annual Meeting, May 3-7, in Glasgow, Scotland. Sun Nuclear will host a lunch symposium, with a welcome from Tom Logan, Mirion CEO, on Sunday, May 5.
"I’m pleased to join my Sun Nuclear colleagues at ESTRO as we debut this landmark evolution of the SunCHECK software. This upcoming release is a significant leap forward, offering high impact functionality to support healthcare providers in delivering optimal care to patients,” said Tom Logan, CEO of Mirion.
Learn more about the SunCHECK platform here.
About Sun Nuclear
Sun Nuclear is part of Mirion Medical, a group of healthcare-focused brands within Mirion. We provide innovative solutions for Radiation Therapy and Diagnostic Imaging centers. More than 5,000 cancer centers worldwide rely on us for independent, integrated Quality Management. With a focus on ongoing support, Sun Nuclear aims to ease technology adoption, enhance workflows and improve outcomes – so that healthcare providers can achieve real results for Patient Safety. Visit us: sunnuclear.com. Follow us: @sunnuclear.
Sun Nuclear, SunCHECK, 1D SCANNER, and PC Electrometer are trademarks or registered trademarks of Mirion Technologies, Inc. and/or its affiliates in the United States and/or other countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240429991805/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting udvider sin teknologiplatform i Frankrig20.3.2026 17:28:00 CET | Pressemeddelelse
Andersen Consulting udvider sit udbud inden for digital transformation med en samarbejdsaftale med Teolia Consulting, et fransk firma, der specialiserer sig i projekt- og produktstyring, cloud-platformsudvikling, datatransformation samt implementering og brug af Atlassian-pakken. Teolia Consulting blev grundlagt i 2014 og hjælper organisationer med at opnå digital performance, fra agile metoder til løsninger, der reducerer lanceringstiden. Virksomhedens ekspertise består i at levere integrerede strategier, der bringer teknologi og organisatorisk forandring i overensstemmelse. Virksomheden arbejder på tværs af brancher, herunder inden for bank- og finanssektoren, forsikring, mode og detailhandel, og hjælper kunder med at få større robusthed og accelerere deres digitale modenhed. "Hos Teolia Consulting mener vi, at ægte transformation opstår, når teknologi og mennesker udvikler sig sammen," sagde Lucienne Jacquet, der er administrerende partner i Teolia. "Ved at samarbejde med Andersen C
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 15:00:00 CET | Press release
- New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 & STOP-HS2) to be highlighted - Featured abstracts for ruxolitinib cream (Opzelura®) and povorcitinib include multiple ePosters in atopic dermatitis, hidradenitis suppurativa and vitiligo Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentation
MUSASHI JAPAN by TAIMATSU Launches “Road to Shogun” – A Journey Through Craftsmanship and Discovery20.3.2026 13:58:00 CET | Press release
Musashi Japan by TAIMATSU Co., Ltd., a contemporary Japanese knife brand rooted in the spirit of craftsmanship and cultural harmony, has announced its newest experiential campaign: “Road to Shogun.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320887471/en/ Designed as the brand’s most ambitious customer journey to date, the campaign invites visitors to explore participating Musashi Japan stores while discovering the traditions, culture and craftsmanship that inspire the brand. Inspired by the journey towards mastery, the experience encourages participants to progress through a series of ranks whilst visiting stores and unlocking rewards that celebrate elements of everyday Japanese culture. At Musashi Japan, craftsmanship is not only about the final product, but also about the path taken to achieve mastery. The Road to Shogun reflects this philosophy by guiding customers through a journey that mirrors the dedication, cu
Futur Delivers Strong Growth and Record Profit in 202520.3.2026 12:05:00 CET | Press release
In 2025, Futur added 21,000 new customers and the inflows amounted to 34 billion kronor. At the end of the year, the total savings capital was 252 billion kronor, an increase of 7% from the previous year and a new record level. "2025 was a record year for Futur. In a market characterized by sharp market fluctuations, Futur continued to invest, grow and deliver strong results. Behind this record performance is stable customer growth, strong inflows and cost discipline. Our close cooperation with over 60 partners gives customers the freedom to choose the asset management and advisory services that best suit them. The strategy of letting the customer choose is appreciated, which is reflected in us welcoming more than 21,000 new customers during the year", says Torgny Johansson, CEO of Futur. "We are optimistic about the future. Futur has great opportunities to continue growing in the coming years by developing innovative and efficient services for savings and pensions. I am proud of how a
Lyten to Establish a Lyten Industrial Hub in Poland20.3.2026 12:00:00 CET | Press release
Lyten announces the establishment of its next Lyten Industrial Hub in Gdańsk, Poland. The hub will bring together key manufacturing and digital resources to support energy infrastructure, the development of artificial intelligence, and the defense sector. In February 2026, Lyten announced the creation of the first Lyten Industrial Hub in Sweden, combining battery production operations there with a 1 GW AI data center campus. Lyten plans to complete its feasibility study by the end of 2026 to determine the full development plan Lyten, the supermaterial applications company and global leader in an energy storage, has announced its interest in establishing a Lyten Industrial Hub in Poland. In 2026, Lyten will conduct a feasibility study to assess manufacturing requirements for Lyten products, potential private and public partnerships, and the necessary energy and utility infrastructure. The industrial hub will be built around Lyten Dwa – the energy storage production plant and R&D center
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom